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Abstract 
Repeated exposure to mild TBI (mTBI) has been linked to an increased risk of Alzheimer’s disease (AD), chronic trau-
matic encephalopathy (CTE) and other neurodegenerative diseases. Some pathological features typically observed 
in AD have been found in postmortem brains of TBI and CTE, hence treatments tested for AD have a potential to be 
effective against r-mTBI outcomes. Neuroinflammation may present a possible answer due to its central role both in 
acute brain injury and in chronic degenerative-like disorders. Our previous studies have shown that drug nilvadipine, 
acting as an inhibitor of spleen tyrosine kinase (SYK), is effective at reducing inflammation, tau hyperphosphorylation 
and amyloid production in AD mouse models. To demonstrate the effect of nilvadipine in the absence of age-related 
variables, we introduced the same treatment to young r-mTBI mice. We further investigate therapeutic mechanisms of 
nilvadipine using its racemic properties. Both enantiomers, (+)-nilvadipine and (−)-nilvadipine, can lower SYK activity, 
whereas (+)-nilvadipine is also a potent L-type calcium channel blocker (CCB) and shown to be anti-hypertensive. 
All r-mTBI mice exhibited increased neuroinflammation and impaired cognitive performance and motor functions. 
Treatment with racemic nilvadipine mitigated the TBI-induced inflammatory response and significantly improved 
spatial memory, whereas (−)-enantiomer decreased microgliosis and improved spatial memory but failed to reduce 
the astroglial response to as much as the racemate. These results suggest the therapeutic potential of SYK inhibition 
that is enhanced when combined with the CCB effect, which indicate a therapeutic advantage of multi-action drugs 
for r-mTBI.
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Introduction
Globally, 61 million individuals are estimated to sustain 
Traumatic brain injury (TBI) each year [5]. In the United 
States alone, TBI affects over 2.5 million people annually, 
with mTBI representing 80% of all TBI cases, and to date 
accounts for more than 13 million cases of long-term 
disability [32]. Repeated exposure to mTBI (r-mTBI) has 
been to linked to higher risks of chronic neurodegen-
erative disorders including Alzheimers disease (AD) and 
Chronic Traumatic Encephalopathy (CTE) [4, 6, 12, 13, 
31]. In fact, the pathologies of late r-mTBI share similar 
features with AD and CTE and include a marked neuro-
inflammatory response, the presence of neurofibrillary 
tangles (NFTs), and to a lesser extent, the presence of 
amyloid-β (Aβ ) pathology [9, 14, 30, 31]. Among them, 
neuroinflammation is a key element of both acute and 
chronic phases of r-mTBI and may represent a target for 
early therapeutic intervention.
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In our previous pre-clinical work on AD, we have 
shown that the drug nilvadipine can reduce inflamma-
tion, decrease tau phosphorylation, and enhance A β 
clearance across the blood brain barrier (BBB), while 
improving cognitive functions [2, 23, 24]. Nilvadipine 
is a dihydropyridine (DHP) that blocks L-type calcium 
channels and exhibits anti-hypertensive properties [3]. 
Nilvadipine is a racemic mixture of two enantiomers: 
(+)-nilvadipine and (−)-nilvadipine. (+)-nilvadipine is 
a L-type calcium channel blocker responsible for the 
anti-hypertensive properties of nilvadipine while (−)-nil-
vadipine is deprived of anti-hypertensive effect [23, 24]. 
Interestingly, we have shown that both enantiomers of 
nilvadipine are able to reduce neuroinflammation, tau 
hyperphosphorylation, and A β production via a mecha-
nism which appears to be independent of L-type calcium 
channel inhibition and mediated by SYK inhibition [23]. 
In a small clinical trial, nilvadipine delayed clinical pro-
gression of MCI to AD [8] while in an open label Phase 
I/IIa clinical study, nilvadipine showed safety and toler-
ability in the AD patients and no adverse effects on blood 
pressure [10]. More recently, in a Phase III randomized, 
placebo-controlled clinical trial for AD (NILVAD, 
n = 510), the very mild AD cases (≥ 25, N = 80) dem-
onstrated a significant reduction in cognitive decline fol-
lowing treatment with nilvadipine compared to placebo 
[1, 11].
Our preclinical data, which demonstrated the ability 
of nilvadipine to suppress these pathologies common to 
both AD and TBI, encouraged us to test this drug in our 
models of r-mTBI. Earlier, we developed a r-mTBI model 
that successfully recapitulates aspects of human TBI 
pathology such as inflammation, axonal injury, and cog-
nitive deficits [18–20]. We further tested a 21-day treat-
ment with nilvadipine in the very old r-mTBI hTau mice 
to mimic brain traumas occurred in the elderly popula-
tion [17]. We chose hTau mice because they express all 
6 isoforms of human tau making it a convenient model 
for mimicking TBI-induced tauopathy, which is often 
observed in the elderly. Interestingly, nilvadipine amelio-
rated inflammation, tau phosphorylation and short-term 
memory deficits induced by r-mTBI. However, in the 
very old mice (24–26 months old), age-driven pathology 
precluded the differentiation of the injury effects from 
age effects. Therefore, in this study, we aimed to deliver a 
similar 21-day treatment with nilvadipine in young hTau 
mice and to assess pathological and cognitive response 
at 3 weeks post last mTBI. We also included treatment 
with the non-vasoactive (non-calcium-channel blocker) 
(−)–nilvadipine enantiomer (internal reference name 
ARC031) to investigate whether treatment effects on TBI 
outcomes required the Ca2+-channel blocking effects of 
racemic nilvadipine.
Methods and materials
Animals
Male and female hTau mice 12–14 weeks old (weight 
19–25 g) were sourced from Jackson Laboratories (Bar 
Harbor, ME). The animals were housed under stand-
ard laboratory conditions (14-h light/10-h dark cycle, 
23 ±  1C, 50 ±  5% humidity) with free access to food 
and water. All procedures were carried out under Insti-
tutional Animal Care and Use Committee (IACUC) 
approval and in accordance with the National Institutes 
of Health Guide for the Care and Use of Laboratory 
Animals.
Experimental groups and study design
A total of 72 mice were randomly assigned to 1 of 6 
groups (n  =  12 per group): repetitive sham/vehicle, 
repetitive sham/nilvadipine, repetitive sham/ARC031, 
repetitive injury/vehicle, repetitive injury/nilvadipine 
and repetitive injury/ARC031. The r-mTBI (total of 5 hits 
with an inter-concussion interval of 48  h) was adminis-
trated to mice as previously described [18, 19, 21, 33, 34]. 
Sham injured animals (5 anesthesia, 48  h apart) under-
went the same procedures and were exposed to anes-
thesia for the same length of time as the mTBI animals. 
Either nilvadipine, ARC031 or vehicle (PBS:PEG/1:1) 
were injected intraperitoneally (100 μL, i.p.) daily for 21 
days, with the first injection administered immediately 
following the last injury. The behavior analysis began 24 h 
after the last mTBI/anesthesia for each group, as shown 
in Fig. 1. Euthanasia was performed 22 days after the last 
mTBI/sham procedure. Researchers were blind to animal 
group assignments during both neurobehavioral experi-
ments and immunohistochemistry.
Injury protocol
All animals were anesthetized with 1.5 L/min of oxygen 
and 3% isoflurane prior to r-mTBI or sham injury. The 
heads were shaved, and mice were placed on a heat-
ing pad to maintain body temperature at 37C to pre-
vent hypothermia. The head of each animal was fixed in 
a stereotaxic frame, and the blunt impactor tip (3 mm 
diameter) was positioned midway to the sagittal suture. 
The injury was triggered at 5 m/s velocity and 1.0 mm 
depth, with a dwell time of 200 ms, using a myNeuroLab 
controller device (Impact OneTM Stereotaxic Impactor, 
Richmond, IL). All mice experienced short-term apnea 
( < 20 s) and showed no skull fractures. All animals were 
allowed to recover from anesthesia on a heating pad and 
then returned to their cages with water and soft food 
access. Sham animals received anesthesia alone for the 
same duration of time as the r-mTBI mice, to control for 
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the effects of repeated anesthesia. Mice were monitored 
daily for any abnormalities in behavior.
Treatment
For convenience, racemic nilvadipine will be referred 
to as “nilvadipine”, while (−)-nilvadipine enantiomer as 
“ARC031” . All mice received either nilvadipine, ARC031 
or vehicle via i.p. injections for 21 days, starting imme-
diately after the last injury/sham (the first injection was 
administered while animals were still under anesthesia). 
The treated groups received 2 mg/kg nilvadipine (equiva-
lent to a human oral dose of 8 mg conferring antihyper-
tensive activity) or 2  mg/kg ARC031 dissolved in a 1:1 
solution of PBS and PEG vehicle solution [23]. The injec-
tion volume (100 μL) was calculated based on the average 
animal’s weight (0.028 kg). Untreated animals underwent 
the same procedure but received vehicle solution only 
(PBS:PEG/1:1). All solutions were freshly prepared every 
day before the injections.
Motor and cognitive function assessment
Motor function was assessed using the Rotarod appara-
tus, and the latency to fall from an accelerating rotating 
rod was measured. Baseline performance was recorded 
1 day prior to the first injury/sham. Rotarod assessment 
started on the day after the last injury/sham proce-
dure and was carried out on days 1, 3, 5 and 7 post-last 
r-mTBI/sham. An acclimation period involved 3 trials 
with a duration of 3 min each and a 3 min rest interval 
in the animal’s home cage between the trials (velocity 
= 5  rpm, no acceleration). The mice were placed back 
on the bar during the acclimation period if they fell. All 
experimental trials, including the baseline trials, lasted 
for 5 min and were conducted with acceleration from 5 
to 50 rpm over the 5 min period. Each animal underwent 
3 trials per day, with a 3 min rest interval between each 
trial. The fall time of each mouse was recorded in sec-
onds. To ensure that fall time would correlate with motor 
coordination, rather than purely grip strength, if a mouse 
clung to the bar for more than 5 consecutive rotations on 
the accelerating rod without walking or making forward 
progress against the rotation of the bar, the time of the 
5th rotation was considered to be the fall time and was 
recorded as such.
Barnes Maze (BM) was initiated on day 8 post-last 
mTBI/sham and lasted for 7 consecutive days to assess 
cognitive function. For 6 days, animals were trained 
to find the target hole which had a black escape box 
underneath. The walls in the room were equipped with 
visual cues and the brightness of the room was consist-
ent throughout testing (7 days). The BM table was 1.2 
m in diameter and has 18 equally spaced holes around 
the perimeter. Every mouse had 4 acquisition trials per 
day, with a duration of 1.5 min each. The starting posi-
tion for each trial during acquisition rotated, beginning 
at one of 4 cardinal directions of the maze and rotating, 
first clockwise (until reaching the initial position again) 
and then counterclockwise. If an animal did not find the 
target hole or did not go inside the box within the time 
limit, the mouse was guided to the target hole by hand. 
Regardless of their success, mice then spent 30 s in the 
box before returning to their cage. On the last day, 24 h 
following the final acquisition trial, a probe trial was con-
ducted during which the animals were placed in the mid-
dle of the maze and had 60 s to find the target hole, from 
which the escape box had been removed. The cumulative 
distance from the target hole, total distance travelled, 
time to find the target hole, and velocity were calculated 
using Noldus Ethovision XT software and analyzed to 
assess spatial memory and learning. Cumulative dis-
tance was measured as the sum of the distance between 
the center point of the mouse and the center of the target 
hole for every video frame from each trial at 30 frames 
per second. This distance stopped accumulating when 
the trial ended, either when the total time had elapsed or 
when the mouse entered the target box. Data were pre-
sented as the raw values of the cumulative distance.
Tissue collection and processing
Animals were euthanized on the day after the last injec-
tion (22 days post-last injury/sham). Mice were anesthe-
tized with 3 % isoflurane and perfused transcardially with 
Fig. 1 Study design
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phosphate-buffered saline (PBS), pH-7.4. After perfusion, 
the brains were post-fixed in a solution of 4% paraform-
aldehyde (PFA) at 4C for 48 h and paraffin-embedded for 
immunohistochemistry. Brain samples fixed in PFA were 
processed in paraffin using the Tissue-Tek VIP (Sakura, 
USA). Sagittal sections were cut at 8  μm using a Leica 
RM2235 microtome and mounted on positively charged 
glass slides. Prior to staining, sections were deparaffi-
nized in xylene and rehydrated in ethanol solutions of 
decreasing concentrations.
Immunohistochemistry
Non‑fluorescent staining for GFAP
Following rehydration, slides were processed with hydro-
gen peroxide for 15 min and heated in citric acid buffer 
(pH-6) for antigen retrieval. Slides were then blocked 
with normal goat serum, washed with PBS, and incu-
bated in a primary antibody for GFAP overnight at 4C 
(GFAP7857983, Aves Labs, Inc., 1:10,000). On the next 
day, slides were processed using the anti-chicken Vec-
taSTAIN ABC Kit and developed with 3,3′-Diaminoben-
zidine (DAB) before mounting.
Non‑fluorescent staining for Iba1
Microglia were stained using an anti-Iba1 antibody 
(ab107159, Abcam). After rehydration, slides were pro-
cessed with hydrogen peroxide for 15 min followed by 
antigen retrieval using citric acid buffer (pH-6). Next, 
slides were blocked with rabbit serum for 1 h at room 
temperature and then incubated with the primary anti-
body (1:1000) overnight. On the next day, samples were 
processed using the anti-goat VectaSTAIN ABC Kit and 
developed with DAB.
Fluorescent staining
GFAP/Iba1/CD68/P‑SYK
Fluorescent staining was performed using the following 
antibodies: Iba1 (ab107159, Abcam), GFAP (7857983, 
Aves Labs), CD68 (ab125212, Abcam) and phosphoryl-
ated spleen tyrosine kinase P-SYK (Tyr525/526) (2710S, 
Cell Signaling). Following rehydration, antigen retrieval 
was performed by heating slides in citric acid buffer for 
7 min in a microwave oven. Next, slides were washed 
with PBS and transferred to a Sudan Black solution for 
15 min to prevent autofluorescence. Slides were then 
blocked for 1 h with 10% donkey serum solution in PBS, 
and primary antibodies for Iba1 (1:300), GFAP (1:1000), 
CD68 (1:500) and P-SYK (1:200) were applied overnight. 
On the next day, secondary antibodies AlexaFluor488 
(A21202, Life Technologies), AlexaFluor647 (A21449, 
Life Technologies), AlexaFluor568 (ab175477, Abcam), 
were applied for P-SYK, GFAP, and Iba1/CD68, respec-
tively. Slides were mounted with ProLong Gold Antifade 
4′,6-diamidino-2-phenylindole (DAPI) Mount. Each 
marker was stained separately except for the double 
staining for Iba1/P-SYK that was performed to evaluate 
colocalization of the two. Fluorescent imaging was per-
formed using a confocal microscope (LSM 800 Zeiss) at 
20× and 63× magnification. Z-stacks were recorded for 
every image and orthogonal projections were obtained to 
enable a 3D representation of the picture.
Immunohistochemical quantification
Imaging of non-fluorescent samples stained for GFAP/
Iba1 was performed on an Olympus DP72 microscope 
at 10× magnification. Further analysis of the images 
included quantification of GFAP and Iba1 signal using 
ImageJ. Images were separated into individual color 
channels (hematoxylin counterstain and DAB chromo-
gen) using the color deconvolution algorithm. Three 
nonoverlapping regions of interest (ROI) of 100 μm2 per 
image were then selected for the hippocampus, the body 
of the corpus callosum and the cortex. A coverage area 
( % ) per ROI was calculated and the mean value for each 
animal was used for further statistical analysis.
MesoScale discovery (MSD) multi‑spot assay
A tau profile was assessed in cortical mouse homogen-
ates using MSD protocol using the Phospho (Thr231)/
Total Tau kit (V-PLEX K15121D) following manufac-
turer’s instructions. First, the calibration solution Tau441 
was prepared according to the kit protocol. Samples and 
controls were diluted twofold in Tau441. Then, the plate 
was blocked with Blocker A for 1  h followed by adding 
the samples and calibrators into the wells. After 1  h of 
incubation, the plate was incubated for 1 h with detection 
antibodies (SULFO-TAG), and the Read Buffer T was 
added to analyze the plate. The plate was washed with the 
Tris Wash Buffer after each step. The plate analysis was 
conducted on the MSD instrument (MESO Quick Plex 
SQ120).
Statistical analysis
All experimental data were analyzed using JMP 12 and 
GraphPad Prism 6 software. The data were checked for 
normality using Skewness-Kurtosis and Goodness of 
Fit. If normal, parametric method one-way ANOVA was 
applied to calculate the significance in the tested groups 
(p values less than 0.05 were considered significant). If 
significant, post-hoc analysis was applied using Turkey’s 
multiple comparison test/Honest Significant Difference 
(HSD). The Turkey’s test compares all possible pairs of 
means between different treatment groups and was con-
sidered significant if p < 0.05 . The Shapiro–Wilk test was 
used if data were not normally distributed. All data were 
transformed to logarithm or square root, when required, 
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to reach normality before further analysis. Repeated-
measure analysis of variance (MANOVA) was used to 
analyze continuous performance of mice in the Barnes 
Maze and Rotarod ( p < 0.05 is significant). Error bars 
represent the standard error of the mean.
Results
Motor assessment
Motor functions were assessed using Rotarod on days 
1, 3, 5 and 7 post-last TBI. Overall, all mice except 
the r-mTBI-vehicle group exhibited at least 40% 
increase in latency to fall over a 7-day period (Fig. 2a). 
R-mTBI-vehicle mice did not demonstrate improve-
ment in their performance when compared to the 
baseline. Nilvadipine treatment in the injured mice 
ameliorated their motor deficits to levels not sig-
nificantly different from sham mice and did not affect 
the behavior in healthy sham mice (r-mTBI-vehicle 
vs. sham-vehicle p < 0.0001 , r-mTBI-nilvadipine vs. 
r-mTBI-vehicle p < 0.001 , sham-nilvadipine vs. sham-
vehicle p > 0.05 , r-mTBI-nilvadipine vs. sham-vehicle 
p > 0.05 , MANOVA). Treatment with ARC031 did not 
show an amelioration of the locomotor deficits in the 
r-mTBI mice ( p > 0.05 , MANOVA).
Fig. 2 a Evaluation of the effect of nilvadipine or ARC031 on motor performance. Mice in the r-mTBI-vehicle group showed a significant decrease 
in their performance compared to the sham-vehicle ( p < 0.001 ). Treatment with nilvadipine ameliorated motor deficits in the r-mTBI mice 
(r-mTBI-nilvadipine vs. r-mTBI-vehicle, p < 0.001 ). In r-mTBI mice treated with ARC031, no differences were observed in the latencies compared to 
the r-mTBI-vehicle ( p > 0.05 ). b–e Evaluation of spatial learning and memory. b Probe data show that r-mTBI-vehicle mice took more time to locate 
the target hole compared to the sham-vehicle controls ( p < 0.05 ). Both nilvadipine ( p < 0.01 ) and ARC031 ( p < 0.05 ) treatments in the r-mTBI 
mice ameliorated impaired memory functions compared to r-mTBI-vehicle ( p < 0.05 ). c–e Compared to sham-vehicle, r-mTBI-vehicle mice exhibit 
learning deficits during the 6 days of acquisition. All injured sham mice travelled greater distance (c, p < 0.001 ; d, p < 0.001 ) and failed to enter the 
box (e, days 2–4, p < 0.01 , days 5–6 p < 0.001 ) compared to sham-vehicle mice. R-mTBI-nilvadipine/ARC031 mice showed an improvement in all 3 
parameters compared to the r-mTBI-vehicle (c cumulative distance p < 0.01/p < 0.01 , d distance traveled p < 0.0001/p < 0.0001 , e latency to target 
box p < 0.05/p < 0.05 ). Distribution (M-male, F-female): sham-vehicle n = 11 (5M, 6F), r-mTBI-vehicle n = 12 (6M, 6F), sham-nilvadipine n = 12 (6M, 
6F), r-mTBI-nilvadipine n = 11 (6M, 5F), sham-ACR031 n = 9 (5M, 4F), r-mTBI-ARC031 n = 9 (5M, 4F). Data are presented as mean ± standard error of 
the mean; significance was calculated using one-way ANOVA and MANOVA
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Memory assessment
Spatial learning and memory were assessed using Barnes 
Maze during days 8–14 post last TBI and the probe trial 
was recorded on day 15. Sham-vehicle mice demon-
strated an 83% decrease of the cumulative distance and 
a 71% decrease in the distance traveled from day 1 to 6 
(Fig. 2c, d). R-mTBI vehicle mice exhibited a 25% reduc-
tion of the cumulative distance during days 1–3 which 
reached a plateau on days 4–6 (r-mTBI-vehicle: day1 vs. 
day6 p < 0.05 , one-way ANOVA). R-mTBI-vehicle mice 
had significantly higher cumulative distance (vs. sham-
vehicle p < 0.001 , MANOVA) and distance traveled (vs. 
sham-vehicle p < 0.0001 , MANOVA) than controls. 
Travel distance in r-mTBI-vehicle mice stayed consistent 
with day 1 during an entire acquisition period (r-mTBI-
vehicle: day1 vs. day6 p > 0.05 , one-way ANOVA). On 
days 2–6, r-mTBI-vehicle mice traveled for a longer time 
than sham-vehicle (r-mTBI-vehicle vs. sham-vehicle: 
for day2 and day3 p < 0.01 ; for day4, day5, and day6 
p < 0.001 , one-way ANOVA). Treatment with nilvadi-
pine in r-mTBI mice lead to a 44% decrease in cumula-
tive distance (r-mTBI-nilvadipine vs. r-mTBI-vehicle 
p < 0.01 , r-mTBI-nilvadipine vs. sham-vehicle p > 0.05 , 
MANOVA) and a 28.6% decrease in the distance trave-
led (r-mTBI-nilvadipine vs. r-mTBI-vehicle p < 0.0001 , 
r-mTBI-nilvadipine vs. sham-vehicle p < 0.01 , 
MANOVA). Similarly, a decrease in the latency to enter 
the target box from day 1 to day 6 was observed for 
sham-vehicle (44%) and sham-nilvadipine (25%) groups 
(Fig.  2e). After r-mTBI, mice took 50% longer to locate 
the box compared to the sham-vehicle, with only tran-
sient improvements on days 3–5. By day 6, a 35% increase 
in time to locate the box was recorded for the r-mTBI-
nilvadipine mice compared to sham-vehicle. This time 
was still notably decreased by 20% when r-mTBI-nilvad-
ipine are compared to r-mTBI-vehicle. Similarly, treat-
ment with ARC031 in r-mTBI mice decreased cumulative 
distance (r-mTBI-ARC031 vs. r-mTBI-vehicle, p < 0.01 , 
MANOVA), distance traveled (r-mTBI-ARC031 vs. 
r-mTBI-vehicle, p < 0.0001 , MANOVA) and latency 
(r-mTBI-ARC031 vs. r-mTBI-vehicle: for day2 p < 0.01 , 
for day3 and day4 p < 0.05 , for day5 and day6 p < 0.01 , 
one-way ANOVA) compared to vehicle-treated r-mTBI 
groups (Fig.  2c–e). During the probe trial, r-mTBI-
vehicle mice spent a significantly longer time locat-
ing the target hole indicating deficits in spatial memory 
(Fig. 2b; r-mTBI-vehicle vs. sham-vehicle p < 0.05 , one-
way ANOVA). Nilvadipine recovered these deficits back 
to the control levels with no effects on healthy sham 
mice (r-mTBI-nilvadipine vs. r-mTBI-vehicle p < 0.01 , 
r-mTBI-nilvadipine vs. sham-vehicle p > 0.05 , one-
way ANOVA). ARC031 also decreased r-mTBI-induced 
memory impairments during the probe trial (Fig.  2b; 
r-mTBI-ARC031 vs. r-mTBI-vehicle p < 0.05 , r-mTBI-
ARC031 vs. sham-vehicle p > 0.05 , one-way ANOVA).
Immunohistochemistry
GFAP staining revealed no gliosis in the healthy tissue of 
sham-vehicle mice (Fig.  3a–d). An increased astroglial 
reactivity was prominent in the r-mTBI-vehicle mice in 
the corpus callosum ( p < 0.05 , one-way ANOVA) and in 
the retrosplenial (RSP) and somatomotor (MO) areas of 
the cortex surrounding the injury site ( p < 0.001 , one-
way ANOVA) (Figs. 3a–d, 4a, c, d). This r-mTBI induced 
increase was reduced by nilvadipine treatment in all three 
analyzed brain areas (corpus callosum p < 0.01 , hip-
pocampus p < 0.05 , cortex p < 0.05 , one-way ANOVA). 
In the r-mTBI-ARC031 mice, a significant decrease of 
astrogliosis was also observed in the corpus callosum 
( p < 0.001 , one-way ANOVA) but not in the cortex 
( p > 0.05 , one-way ANOVA). Immunofluorescent analy-
sis confirmed a significant decrease of astrogliosis in the 
superficial layers of the cortex in the r-mTBI-nilvadipine 
versus r-mTBI-vehicle mice but not in r-mTBI-ARC031 
mice (Fig.  4a, c). Moreover, a decreased fluorescent 
intensity for astroglial marker GFAP was shown in the 
hippocampus in both r-mTBI-nilvadipine and r-mTBI-
ARC031 cohorts compared to r-mTBI-vehicle controls 
(Fig. 4b, d).
IHC staining for Iba1 revealed a 50% increase in micro-
gliosis in the r-mTBI-vehicle mice compared to sham-
vehicle mice in the corpus callosum ( p < 0.01 , one-way 
ANOVA) but not in the cortex ( p > 0.05 , one-way 
ANOVA) (Fig.  5a, b). In the r-mTBI-nilvadipine mice, 
Iba1 showed a 50% decrease (to close to sham levels) 
compared to the r-mTBI-vehicle mice ( p < 0.05 , one-
way ANOVA). Similarly, treatment with ARC031 reduced 
Iba1 immunostaining in the corpus callosum of r-mTBI-
ARC031 mice compared to r-mTBI-vehicle ( p < 0.01 , 
one-way ANOVA).
Immunofluorescence for CD68, a lysosomal protein 
expressed in high levels by macrophages and activated 
microglia and in low levels by resting microglia, showed 
an increased signal in the corpus callosum of r-mTBI 
mice compared to the sham-vehicle (Fig. 6, p < 0.0001 ). 
Treatment with nilvadipine decreased CD68 in the 
r-mTBI mice compared to the vehicle treated TBI mice 
( p < 0.001 ). Nilvadipine did not affect CD68 signal in the 
sham mice.
SYK response was measured by targeting the SYK 
phosphorylation site Tyr525/526, which is the main site 
involved in receptor-mediated SYK activation [27]. Fluo-
rescent signal for P-SYK (Tyr 525/526) was detected in 
the r-mTBI-vehicle mice but absent in the young sham-
vehicle mice (Fig.  7). Patchy P-SYK distribution was 
found in the corpus callosum of r-mTBI-vehicle mice but 
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it was not easily detected and could not be quantified. 
The P-SYK images of the r-mTBI-vehicle group presented 
on Fig. 7 are representative of n = 12 analyzed samples. 
All detected areas of P-SYK accumulation were colocal-
ized with Iba1-immunoreactive microglia. In the r-mTBI-
nilvadipine and r-mTBI-ARC031 mice, there was no 
evidence for P-SYK in the corpus callosum as shown on 
the representative images from the total n = 10 and n = 7 
analyzed images, respectively.
Tau levels were measured by immunoassay using 
MSD Phospho(Thr231)/Total Tau kit (Additional 
file  1). No r-mTBI-induced increase of total or p-tau 
was observed in cortical tissue compared to the sham-
vehicle group. Similarly, treatment with nilvadipine 
in either sham or r-mTBI mice did not alter levels of 
p-tau compared to the respective controls. A signifi-
cant decrease in total tau was observed in sham-nilvad-
ipine (vs. sham-vehicle, p < 0.01 and r-mTBI-vehicle, 
Fig. 3 Evaluation of the effects of nilvadipine or ARC031 on astrocytes activation. a–b An increase in the area of GFAP staining was observed in 
the r-mTBI-vehicle mice compared to sham-vehicle ( p < 0.001 ). This increase was suppressed in the r-mTBI-nilvadipine mice ( p < 0.05 ). c–d In 
the corpus callosum, r-mTBI-vehicle mice also exhibited elevated levels of GFAP compared to the sham-vehicle mice ( p < 0.001 ). Treatment with 
nilvadipine and ARC031 in the r-mTBI mice reduced astrogliosis ( p < 0.0001 , p < 0.001 , respectively) compared to respective TBI-vehicle. Distribution 
of n “cortex/hippocampus” (M-male, F-female): sham-vehicle n = 5/8 (3M, 2F/4M, 4F), r-mTBI-vehicle n = 6/8 (3M, 3F/4M, 4F), sham-nilvadipine 
n = 6/8 (3M, 3F/4M, 4F), r-mTBI-nilvadipine n = 5/8 (2M, 3F/4M, 4F), sham-ACR031 n = 5/8 (2M, 3F/4M, 4F), r-mTBI-ARC031 n = 6/8 (3M, 3F/4M, 4F). 
Data are presented as mean ± standard error of the mean; significance was calculated using one-way ANOVA. Scale bars equal 200 μm
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p < 0.001 ) and in r-mTBI-nilvadipine (vs. r-mTBI-vehi-
cle, p < 0.01 ) mice.
Discussion
Our model of r-mTBI demonstrates clear glial activa-
tion with motor and memory impairments in the first 
21 days following the last injury. Areas with notable glial 
response included the corpus callosum (CD68, Iba1, 
GFAP) and cortical regions MO and RSP (GFAP). Inter-
estingly, the retrosplenial (RSP) region, which is involved 
in spatial cognition, appears to show evidence of neu-
roinflammation after TBI in our model, together with 
the corpus callosum, and may therefore contribute to 
the observed cognitive impairment in our animals [15]. 
Treatment with nilvadipine attenuated both motor and 
memory deficits induced by r-mTBI and reduced astro-
gliosis (cortex, corpus callosum) and microgliosis (corpus 
callosum) to the levels observed in sham mice.
We have previously demonstrated that nilvadipine 
exhibits therapeutic properties by inhibiting SYK phos-
phorylation, which is linked to neuroinflammation, 
tau phosphorylation and cognitive deficits [23]. In AD 
mouse models, we have shown that SYK is activated in 
dystrophic neurites around amyloid deposits as well as 
in a subset of activated microglia, while SYK is upreg-
ulated in neurons displaying pathological tau species 
[27]. In our previous study, we showed that r-mTBI in 
aged mice caused patchy accumulation of P-SYK in the 
corpus callosum, usually colocalizing with amoeboid 
microglia, suggesting that SYK activation could play a 
crucial role in acute and sub-acute inflammation after 
mTBI [17]. Nilvadipine was able to reduce P-SYK in 
both mouse models of AD and aged r-mTBI [17, 23]. 
In the current study, P-SYK colocalized with micro-
glia was also detected in the corpus callosum similar 
to the distribution pattern we previously observed in 
aged r-mTBI mice [17]. Nilvadipine decreased P-SYK 
signal in the r-mTBI mice in selected areas of corpus 
callosum and did not affect its signal in the sham mice. 
The results presented are based on the qualitative anal-
ysis, and the role of SYK in r-mTBI will be evaluated in 
future studies.
Fig. 4 Immunofluorescent images of GFAP signal in cortex (a) and hippocampus (b). In the r-mTBI-vehicle mice, strong GFAP signal was found in 
cortex under the injury site spreading into the deeper layers including retrosplenial and somatomotor cortical regions (a, e). In r-mTBI-nilvadipine 
mice, no GFAP signal was found in similar cortical (a, c) or hippocampal regions (b, d). In r-mTBI-ARC031 mice, GFAP signal was significantly reduced 
in hippocampus (b, d), but not in cortex (a, c), compared to the r-mTBI-vehicle group. Cortical GFAP in r-mTBI-ARC031 was not significantly different 
from sham-vehicle (d). Distribution of n in “cortex/hippocampus” (M-male, F-female): sham-vehicle n = 4/6 (2M, 2F/3M, 3F), r-mTBI-vehicle n = 5/8 
(3M, 2F/5M, 3F), sham-nilvadipine n = 6/6 (3M, 3F/4M, 2F), r-mTBI-nilvadipine n = 5/7 (2M, 3F/3M, 4F), sham-ACR031 n = 5/5 (2M, 3F/3M, 2F), 
r-mTBI-ARC031 n = 4/5 (2M, 2F/4M, 1F). Data are presented as mean ± standard error of the mean; significance was calculated using one-way 
ANOVA. Scale bars equal 20 μm for cortex and 200 μm for hippocampus
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Previously, we have reported that nilvadipine success-
fully reduced phosphorylated tau in the aged r-mTBI 
mice [17], but it failed to do so in our current study. 
One possible reason may be the lack of r-mTBI-induced 
increase of p-tau due to the young age of mice (3 months 
old) which we have previously noted, although such 
increases are apparent in older hTau mice where tau 
pathology already exists [22]. Such age-dependent dif-
ferences in p-tau in hTau mice may affect therapeutic 
response to nilvadipine. Nevertheless, nilvadipine did 
attenuate total tau levels in both sham and r-mTBI mice 
suggesting its ability to suppress total tau regardless of 
injury. Consistent with this, we have previously reported 
that SYK inhibition at 30 weeks of age (when tau pathol-
ogy is prevalent) decreased total tau in P301S mice [28]. 
Schweig et  al. demonstrated that inhibition of SYK did 
not affect expression of total tau but rather increased its 
degradation via an mTOR-dependent autophagy pathway 
[28].
The SYK inhibitory properties of nilvadipine have been 
previously demonstrated in mouse models of AD and 
tauopathies [23], but more work is required to confirm 
that this is the mechanism through which it elicits the 
favorable responses described in this study. Nilvadipine 
is also an L-type Ca2+ channel blocker [26] and similar 
compounds have been proposed as having therapeu-
tic benefit for TBI and have been investigated in several 
clinical trials (albeit these were more severe TBI cases) 
[35]. Prevention of calcium influx through secondary 
mechanisms was also shown to be effective in acute TBI 
Fig. 5 a–b Effects of nilvadipine on microglia in the r-mTBI mice. After r-mTBI, Iba1 signal was increased in the CC compared to sham-vehicle 
( p < 0.01 ). A significant decrease of Iba1 was shown in the r-mTBI mice after treatment with nilvadipine ( p < 0.05 ) and ARC031 ( p < 0.01 ). 
Distribution (M-male, F-female): sham-vehicle n = 5 (2M, 3F), r-mTBI-vehicle n = 5 (1M, 4F), sham-nilvadipine n = 5 (3M, 2F), r-mTBI-nilvadipine 
n = 6 (4M, 2F), sham-ACR031 n = 4 (2M, 2F), r-mTBI-ARC031 n = 7 (5M, 2F). Data were analyzed using one-way ANOVA. Scale bars equal 20 μm
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pathology. For example, glutamate release following pri-
mary injury leads to rapid activation of NMDA receptors 
and calcium overload whereas ongoing secondary injury 
produces downregulation of NMDA receptor expres-
sion [7, 16]. In multiple TBI models, NMDA antagonists 
were able to prevent calcium overload when adminis-
tered within 24–72 h post TBI [29] while treatment with 
NMDA agonists at acute timepoints (8 and 16 h post 
TBI) was not effective. Later administration of these ago-
nists, however, improved synaptic plasticity and neuro-
logical functions (for review see [16]). However, a review 
of 8 clinical trials that tested CCBs in patients with severe 
TBI, traumatic subarachnoid hemorrhage (tSAH) and 
diffuse axonal injury (DAI) identified no significant ben-
eficial effects of CCBs [35].
We have previously shown efficacy of the non-blood-
pressure-lowering enantiomer of nilvadipine ((−)-nil-
vadipine/ARC031) in the controlled cortical impact 
mouse model of TBI (Ferguson, pers. comm). Here, 
we introduced the (−) enantiomer ARC031 into mice 
to test for the role of non-calcium channel blocking 
effects of nilvadipine. Interestingly, ARC031 showed a 
slightly different effect in the r-mTBI mice compared 
to racemic nilvadipine. First, it did not attenuate motor 
deficits, but it did improve memory impairment in the 
r-mTBI mice. Second, it reduced astrogliosis in the 
corpus callosum but, unlike nilvadipine, had no effect 
on reactive astrocytes in the cortex. It did, however, 
decrease microgliosis in the corpus callosum of r-mTBI 
mice. Third, it decreased SYK phosphorylation in the 
Fig. 6 a Immunofluorescent imaging of CD68 in corpus callosum. b Quantification of the fluorescent intensity of CD68 signal demonstrated an 
increased distribution of CD68 macrophages in the TBI-vehicle mice compared to controls ( p < 0.0001 ) and a decreased signal after treatment with 
nilvadipine ( p < 0.001 ). Distribution (M-male, F-female): sham-vehicle n = 4 (2M, 2F), r-mTBI-vehicle n = 4 (1M, 3F), sham-nilvadipine n = 4 (1M, 3F), 
r-mTBI-nilvadipine n = 4 (2M, 2F). Data were analyzed using one-way ANOVA. Scale bars equal 100 μm
Page 11 of 13Morin et al. acta neuropathol commun           (2020) 8:166  
corpus callosum in a similar manner to nilvadipine. The 
lack of effect of (−) enantiomer ARC031 (compared to 
racemic nilvadipine) on motor outcomes may be linked 
to the effects of nilvadipine on cerebral blood flow or 
calcium-associated pathways; possibly the effects on 
cortical astrogliosis may also be related to vascular 
involvement of nilvadipine that is absent in ARC031. 
In a previous study in the TgAPPsw mouse model of 
Alzheimer’s disease, we treated 13-month old mice, 
which mimic AD-like pathology including reduced 
cerebral blood flow (CBF), with nilvadipine (1  mg/kg) 
daily for 15 days, and they demonstrated an increase in 
CBF compared to the vehicle-treated mice [25]. Thus, 
the positive effects of nilvadipine treatment after TBI 
could, at least in part, result from its cerebrovascular 
influence. Nilvadipine remains a plausible candidate 
compared to most other DHPs due to its ability to cross 
BBB and to inhibit SYK activation. Further studies will 
look into the use of other SYK inhibitors combined 
with anti-hypertensive drugs in our 5r-mTBI model to 
validate our hypotheses.
Conclusion
Current work presents novel data that suggest that SYK 
could represent an effective therapeutic target in our 
preclinical model of r-mTBI, wherein SYK inhibition 
decreases TBI-dependent gliosis and improves cogni-
tive and motor functions. Compared to the non-vas-
oactive (−)-nilvadipine, racemic nilvadipine appears 
slightly superior at mitigating behavioral and pathologi-
cal impairments following TBI, suggesting that L-type 
calcium channel inhibition in addition to SYK inhibition 
contributed to the beneficial effects observed. These find-
ings are important for the TBI field as they elaborate on 
potential therapeutic mechanisms and contribute to drug 
discovery research for brain trauma. Additional studies 
are ongoing to validate the contribution of SYK-depend-
ent mechanisms in r-mTBI.
Fig. 7 Representative images of GFAP, P-SYK and Iba1 in corpus callosum. No sham animals showed reactive astrocytes, microgliosis or signs of 
P-SYK. In the r-mTBI-vehicle mice, microglia appear to acquire amoeboid morphology and colocalize with P-SYK accumulations. Treatment with 
nilvadipine or ARC031 also eliminated detection of P-SYK in the corpus callosum in the areas near Iba1-reactive microglia. Distribution (M-male, 
F-female): sham-vehicle n = 10 (5M, 5F), r-mTBI-vehicle n = 12 (6M, 6F), sham-nilvadipine n = 11 (5M, 6F), r-mTBI-nilvadipine n = 10 (5M, 5F), 
sham-ACR031 n = 8 (4M, 4F), r-mTBI-ARC031 n = 7 (3M, 4F). Scale bars equal 10 μm
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Additional file 1. Biochemical analysis of cortical p-tau (pThr-231) (A), 
total tau (DA9) (B) and the ratio of p-tau/total tau (C). No significant 
differences were shown between the cohorts for p-tau (A). Total tau was 
decreased in both sham-nilvadipine (p<0.001) and r-mTBI-nilvadipine 
(p<0.01) groups compared to r-mTBI-vehicle mice (B). A decrease in total 
tau was also recorded in sham-nilvadipine vs sham-vehicle mice (p<0.01) 
(B). The ratio of p-tau/total tau was increased in sham-nilvadipine mice 
compared to both sham-vehicle and r-mTBI-vehicle mice. Each cohort had 
n=8 (4M,4F). Data are presented as mean ±  standard error of the mean; 
significance was calculated using one-way ANOVA.
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